SCHEMBL19840552

SCHEMBL19840552

Cc1cccc(C(O)C(C)C(C)(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.42
ADRB1 P08588 1/20 0.42
MIF P14174 1/20 0.42
HTR2A P28223 1/20 0.42
ADRA1A P35348 1/20 0.42
HTR2B P41595 1/20 0.42
EPHX1 P07099 1/20 0.41
ACHE P22303 2/20 0.41
AOC3 Q16853 1/20 0.39
SLC6A4 P31645 1/20 0.38
CASR P41180 1/20 0.36
MAPKAPK2 P49137 1/20 0.35
LMNA P02545 2/20 0.35
HIF1A Q16665 2/20 0.35
ADRA2A P08913 1/20 0.35
ADRA2C P18825 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TP53 P04637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6055386 0.84 ACHE (0.48) ACP3ADRB1MIFHTR2AADRA1A
SCHEMBL11606507 0.83 ACHE (0.52) ACP3ADRB1MIFHTR2AADRA1A
SCHEMBL23347515 0.80 ACP3 (0.44) ACP3ADRB1MIFHTR2AADRA1A
SCHEMBL10415544 0.80 ACP3 (0.44) ACP3ADRB1MIFHTR2AADRA1A
SCHEMBL14357378 0.79 SLC6A4 (0.57) HTR2AADRA1AAOC3SLC6A4LMNA
SCHEMBL9969411 0.79 SLC6A4 (0.57) HTR2AADRA1AAOC3SLC6A4LMNA
SCHEMBL14357099 0.79 SLC6A4 (0.57) HTR2AADRA1AAOC3SLC6A4LMNA
SCHEMBL12435659 0.79 SLC6A4 (0.57) HTR2AADRA1AAOC3SLC6A4LMNA
SCHEMBL12939631 0.79 SLC6A4 (0.57) HTR2AADRA1AAOC3SLC6A4LMNA
SCHEMBL9969410 0.79 SLC6A4 (0.57) HTR2AADRA1AAOC3SLC6A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10787480-B2 Cytotoxic peptides and conjugates thereof NOVARTIS AG (CH) 2020-09-29 US disclosed
US-9884817-B2 Auristatin derivatives and conjugates thereof NOVARTIS AG (CH) 2018-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10787480-B2 Cytotoxic peptides and conjugates thereof CD47, NGLY1, VIP ACP3 1563/4885ADRB1 4492/4885MIF 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.